期刊
THROMBOSIS AND HAEMOSTASIS
卷 119, 期 8, 页码 1212-1221出版社
GEORG THIEME VERLAG KG
DOI: 10.1055/s-0039-1687877
关键词
Btk inhibitor; platelet; bleeding; GPVI; GPIb; X-linked agammaglobulinemia
资金
- Deutsche Forschungsgemeinschaft [SFB1123/B08]
- August-Lenz foundation
Bruton's tyrosine kinase (Btk) is essential for B cell differentiation and proliferation, but also platelets express Btk. Patients with X-linked agammaglobulinemia due to hereditary Btk deficiency do not show bleeding, but a mild bleeding tendency is observed in high dose therapy of B-cell malignancies with ibrutinib and novel second-generation irreversible Btk inhibitors (acalabrutinib and ONO/GS-4059). This review discusses recent studies that may explain this apparent paradox and gives mechanistic insights that suggest a unique potential of low dose irreversible Btk inhibitors as atherothrombosis-focused antiplatelet drugs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据